We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
In cooperation with Association of Corporate Counsel
  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-10 of 19

U.S. Trade Rep launches WTO action against India

  • Shook Hardy & Bacon LLP
  • -
  • India, USA
  • -
  • February 13 2014

U.S. Trade Representative Michael Froman has announced that the United States has requested dispute settlement consultations with India before the

India-based company’s drugs barred from U.S. market

  • Shook Hardy & Bacon LLP
  • -
  • India, USA
  • -
  • January 30 2014

The U.S. Food and Drug Administration (FDA) has prohibited imported drug products from a Ranbaxy Laboratories, Inc. facility in India due to

India to ban PET packaging for certain pharmaceuticals

  • Shook Hardy & Bacon LLP
  • -
  • India, USA
  • -
  • January 9 2014

Citing increasing concerns about potential adverse health effects, the Indian Health Ministry is reportedly considering prohibiting the use of

Indian pharma interests challenge U.S. allegations of discriminatory treatment

  • Shook Hardy & Bacon LLP
  • -
  • India, USA
  • -
  • August 29 2013

According to a news source, the Indian Pharmaceutical Alliance (IPA) has challenged U.S. allegations that India's Patent Act discriminates against

House Subcommittee considers India’s pharmaceutical patent policies

  • Shook Hardy & Bacon LLP
  • -
  • India, USA
  • -
  • July 11 2013

During a recent hearing before the Subcommittee on Commerce, Manufacturing, and Trade of the House Energy & Commerce Committee, witnesses reportedly

India holds out among countries requiring transparency in industry payments

  • Shook Hardy & Bacon LLP
  • -
  • India
  • -
  • June 20 2013

According to a news source, while many countries have instituted disclosure obligations on health-care companies, often pharmaceutical and

Indian Supreme Court rules Novartis cancer drug change not patentable

  • Shook Hardy & Bacon LLP
  • -
  • India
  • -
  • April 4 2013

The Supreme Court of India has rejected the patent application filed by Novartis AG for a beta crystalline form of its cancer drug Gleevec, also

UK and India to fund genomics and bioinformatics tech research

  • Shook Hardy & Bacon LLP
  • -
  • India, United Kingdom
  • -
  • April 4 2013

According to the U.K.'s Biotechnology and Biological Sciences Research Council (BBSRC), up to £10 million has been jointly pledged by the council and

Drug makers complain about slow regulatory approvals in India

  • Shook Hardy & Bacon LLP
  • -
  • Global, India
  • -
  • February 21 2013

Pharmaceutical companies have reportedly begun shifting their clinical trials out of India, claiming that bureaucrats have been slow to approve them

Drug launch within six months of controller general approval now required in India

  • Shook Hardy & Bacon LLP
  • -
  • India
  • -
  • January 24 2013

According to a news source, the Drugs Controller General of India (CG) has announced that pharmaceutical companies failing to launch their drugs